SubsidieMeestersProstate cancer diagnostics using a non-invasive test based on innovative glycan-based scanning
ProSCAN aims to clinically validate a non-invasive liquid biopsy test for early-stage prostate cancer detection, potentially reducing unnecessary biopsies and associated costs significantly.
Projectdetails
Introduction
Prostate cancer (PCa) is the 2nd most frequent cancer in men with 1.4M new annual cases and nearly 0.4M deaths worldwide in 2020. PCa incidence is expected to increase to 2.1M cases and 0.6M annual deaths by 2035. Statistically, 1 in 8 men will get PCa in their lifetime.
Importance of Early Detection
However, nearly 50% of cancer deaths may be avoided if PCa were detected at early stages. Survival is proportional to the stage reached at the time of diagnosis - hence early-stage diagnostics is key to reduce mortality.
Project Aim
Our aim is to clinically validate and register ProSCAN, an affordable, non-invasive next-generation liquid biopsy PCa diagnostic test with a final accuracy of up to 90%.
Innovation in Diagnostics
The ProSCAN is the first test for early-stage PCa diagnostics based on glycan analysis in blood. ProSCAN will identify healthy men and those at risk of PCa, who need a confirmatory biopsy.
Impact on Healthcare
Being so accurate, ProSCAN will eliminate approximately 1.6M avoidable biopsies with the cost of around €1.5bn (in the EU and the US alone).
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.987.387 |
| Totale projectbegroting | € 2.839.125 |
Tijdlijn
| Startdatum | 1-10-2021 |
| Einddatum | 29-2-2024 |
| Subsidiejaar | 2021 |
Partners & Locaties
Projectpartners
- GLYCANOSTICS SROpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patientsDoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patients
DoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Prostate Diagnosis using Optical Coherence TomographyThe PROCT project aims to enhance prostate cancer diagnosis by developing a semiautonomous robotic system using Optical Coherence Tomography for accurate, in vivo lesion analysis without biopsies. | ERC Proof of... | € 150.000 | 2022 | Details |
Prostate Cancer Diagnosis, Localisation and Characterisation using UltrasoundPCaVision aims to enhance prostate cancer diagnosis using cost-effective ultrasound imaging and algorithms, improving patient access and reducing healthcare costs across 16 EU clinics. | EIC Transition | € 1.950.000 | 2022 | Details |
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic CancerLASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly. | EIC Pathfinder | € 2.988.461 | 2024 | Details |
Protein Ruler to Create Affordable Biosensor Diagnosis for the ManyThis project aims to develop a simple, portable, and cost-effective quantitative test for ovarian cancer biomarkers to enhance early detection and improve patient outcomes. | ERC Proof of... | € 150.000 | 2023 | Details |
AI and Robotics for Prostate BiopsyThe ROBIOPSY project aims to develop a robotic prostate biopsy prototype for clinical trials, enhancing diagnostic accuracy and addressing health economics for improved cancer treatment. | EIC Transition | € 2.499.141 | 2023 | Details |
Prostate Diagnosis using Optical Coherence Tomography
The PROCT project aims to enhance prostate cancer diagnosis by developing a semiautonomous robotic system using Optical Coherence Tomography for accurate, in vivo lesion analysis without biopsies.
Prostate Cancer Diagnosis, Localisation and Characterisation using Ultrasound
PCaVision aims to enhance prostate cancer diagnosis using cost-effective ultrasound imaging and algorithms, improving patient access and reducing healthcare costs across 16 EU clinics.
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly.
Protein Ruler to Create Affordable Biosensor Diagnosis for the Many
This project aims to develop a simple, portable, and cost-effective quantitative test for ovarian cancer biomarkers to enhance early detection and improve patient outcomes.
AI and Robotics for Prostate Biopsy
The ROBIOPSY project aims to develop a robotic prostate biopsy prototype for clinical trials, enhancing diagnostic accuracy and addressing health economics for improved cancer treatment.